Abstract
Deposition of amyloid-β (Aβ) in the cerebral cortex is thought to be a pivotal event in Alzheimer’s disease (AD) pathogenesis with a significant genetic contribution. Molecular imaging can provide an early noninvasive phenotype, but small samples have prohibited genome-wide association studies (GWAS) of cortical Aβ load until now. We employed florbetapir (18F) positron emission tomography (PET) imaging to assess brain Aβ levels in vivo for 555 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). More than six million common genetic variants were tested for association to quantitative global cortical Aβ load controlling for age, gender and diagnosis. Independent genome-wide significant associations were identified on chromosome 19 within APOE (apolipoprotein E) (rs429358, P=5.5 × 10−14) and on chromosome 3 upstream of BCHE (butyrylcholinesterase) (rs509208, P=2.7 × 10−8) in a region previously associated with serum BCHE activity. Together, these loci explained 15% of the variance in cortical Aβ levels in this sample (APOE 10.7%, BCHE 4.3%). Suggestive associations were identified within ITGA6, near EFNA5, EDIL3, ITGA1, PIK3R1, NFIB and ARID1B, and between NUAK1 and C12orf75. These results confirm the association of APOE with Aβ deposition and represent the largest known effect of BCHE on an AD-related phenotype. BCHE has been found in senile plaques and this new association of genetic variation at the BCHE locus with Aβ burden in humans may have implications for potential disease-modifying effects of BCHE-modulating agents in the AD spectrum.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698–712.
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362–381.
Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665–672.
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837–1844.
Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C . The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010; 26: 84–93.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280–292.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921–923.
Kim J, Basak JM, Holtzman DM . The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287–303.
Furst AJ, Kerchner GA . From alois to amyvid: seeing Alzheimer disease. Neurology 2012; 79: 1628–1629.
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275–283.
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669–678.
Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202–211 e207.
Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221–229.
Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S et al. Alzheimer's disease neuroimaging initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement 2010; 6: 265–273.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR . Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955–959.
Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012; 44: 552–561.
Pe'er I, Yelensky R, Altshuler D, Daly MJ . Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008; 32: 381–385.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.
Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI . SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938–2939.
Petersen RC . Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364: 2227–2234.
Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB et al. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Cogn Neuropsychiatry 2009; 14: 391–418.
Kendler KS, Neale MC . Endophenotype: a conceptual analysis. Mol Psychiatry 2010; 15: 789–797.
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3: 89ra57.
Holtzman DM, Morris JC, Goate AM . Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011; 3: 77sr71.
Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 2012; 135: 2155–2168.
Lehmann DJ, Johnston C, Smith AD . Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6: 1933–1936.
Darvesh S, Hopkins DA, Geula C . Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131–138.
Guillozet AL, Smiley JF, Mash DC, Mesulam MM . Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909–918.
Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008; 18: 289–298.
Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH et al. Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett 2008; 442: 297–299.
Lane RM, He Y . Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimers Dement, advance online publication, 10 March 2012; doi:10.1016/j.jalz.2010.12.005.
Farlow MR, Miller ML, Pejovic V . Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408–422.
Sabbagh MN, Farlow MR, Relkin N, Beach TG . Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? Alzheimers Dement 2006; 2: 118–125.
Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C . Butyrylcholinesterase is associated with beta-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2012; 71: 2–14.
Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 2011; 32: 2320, e2315-2320.e2332.
Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H et al. The apolipoprotein E ɛ4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobio Aging 2011; 32: 1236–1248.
Lane RM, He Y . Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ɛ4, and hyperhomocysteinemia in neurodegenerative dementias. MedHypotheses 2009; 73: 230–250.
Iwasaki T, Yoneda M, Nakajima A, Terauchi Y . Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007; 46: 1633–1639.
Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1): S16.
Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR et al. GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Hum Mol Genet 2011; 20: 4504–4514.
Kapranov P, Willingham AT, Gingeras TR . Genome-wide transcription and the implications for genomic organization. Nat Rev Genet 2007; 8: 413–423.
Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE . A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003; 23: 2665–2674.
Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest 2012; 122: 1339–1353.
Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630–1645.
Acknowledgements
Data collection and sharing for this project was supported by the ADNI National Institutes of Health (NIH) grant U01 AG024904 (PI: Michael W Weiner, MD, VA Medical Center and University of California, San Francisco, CA, USA). Funding sources for ADNI include the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering, the US Food and Drug Administration, the non-profit partners of the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation and the Dana Foundation, and the following private sector contributors: Abbott, AstraZeneca AB, Amorfix, Bayer Schering Pharma AG, Bioclinica Inc, Biogen Idec, Bristol–Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, Innogenetics, IXICO, Janssen Alzheimer Immunotherapy, Johnson and Johnson, Eli Lilly and Co, Medpace Inc, Merck and Co, Inc, Meso Scale Diagnostic & LLC, Novartis AG, Pfizer Inc, F Hoffman–La Roche, Servier, Synarc, Inc and Takeda Pharmaceuticals. Private sector contributions to ADNI are facilitated by the Foundation for the NIH (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education. The study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego, CA, USA and ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of Los Angeles, CA, USA. Additional ADNI support comes from the NIH grants P30 AG010129, K01 AG030514 and U24 AG21886. Data management and the specific analyses reported here were supported by NSF IIS-1117335 and NIH R01 AG19771, P30 AG10133, R01 LM011360, K24 AG027841, K99 LM011384.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
Dr Jagust has served as a consultant to TauRx Therapeutics Ltd, GE Healthcare, Siemens, Synarc and Janssen Alzheimer Immunotherapy. Dr Weiner has served on scientific advisory boards for Eli Lilly, Araclon, Institut Catala de Neurociencies Aplicades, the Gulf War Veterans Illnesses Advisory Committee, Biogen Idec and Pfizer; has served as a consultant to Astra Zeneca, Araclon, Medivation/Pfizer, Ipsen, TauRx Therapeutics Ltd, Bayer Healthcare, Biogen Idec, Exonhit Therapeutics, Servier, Synarc, Janssen, Harvard University and KLJ Associates; has received funding for travel from NeuroVigil Inc, CHRU Hôpital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Eli Lilly, Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, Clinical Trials on Alzheimer’s Disease, the AD/PD Meeting, Paul Sabatier University, Novartis, Tohoku University, Fundacio ACE and Travel eDreams, Inc; has received honoraria from NeuroVigil, Inc, Institut Catala de Neurociencies Aplicades, PMDA/Japanese Ministry of Health, Labor and Welfare, Tohoku University and the Alzheimer’s Drug Discovery Foundation; has received research support from Merck and Avid; and has stock options for Synarc and Elan. Dr Saykin has received investigator-initiated research funding from Welch Allyn and Siemens Healthcare, and has served as a consultant or advisory board member for Siemens Healthcare and Eli Lilly. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Rights and permissions
About this article
Cite this article
Ramanan, V., Risacher, S., Nho, K. et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry 19, 351–357 (2014). https://doi.org/10.1038/mp.2013.19
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2013.19
Keywords
This article is cited by
-
Genome-Wide association study of quantitative biomarkers identifies a novel locus for alzheimer’s disease at 12p12.1
BMC Genomics (2022)
-
Regulatory role of local tissue signal Del-1 in cancer and inflammation: a review
Cellular & Molecular Biology Letters (2021)
-
MCC-SP: a powerful integration method for identification of causal pathways from genetic variants to complex disease
BMC Genetics (2020)
-
Realistic simulation of virtual multi-scale, multi-modal patient trajectories using Bayesian networks and sparse auto-encoders
Scientific Reports (2020)
-
Phosphoinositide-3-kinase regulatory subunit 1 gene polymorphisms are associated with schizophrenia and bipolar disorder in the Han Chinese population
Metabolic Brain Disease (2020)